Cediranib
Cediranib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 3, vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 1, mast/stem cell growth factor receptor Kit, platelet-derived growth factor receptor alpha, and platelet-derived growth factor receptor beta. In addition, it is known to target macrophage colony-stimulating factor 1 receptor and receptor-type tyrosine-protein kinase FLT3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 7 | 4 | — | 1 | 14 |
| Glioblastoma | D005909 | EFO_0000515 | 4 | 5 | 1 | — | — | 9 | |
| Colorectal neoplasms | D015179 | 4 | 6 | 2 | — | — | 9 | ||
| Fallopian tube neoplasms | D005185 | 2 | 5 | 2 | — | — | 7 | ||
| Endometrioid carcinoma | D018269 | 1 | 5 | 2 | — | — | 6 | ||
| Lung neoplasms | D008175 | C34.90 | 3 | 2 | 2 | — | — | 6 | |
| Acinar cell carcinoma | D018267 | — | 3 | 2 | — | — | 4 | ||
| Biliary tract neoplasms | D001661 | C24.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 15 | 3 | — | — | — | 18 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 6 | — | — | 1 | 9 |
| Non-small-cell lung carcinoma | D002289 | 4 | 4 | — | — | — | 8 | ||
| Renal cell carcinoma | D002292 | 2 | 4 | — | — | — | 6 | ||
| Gliosarcoma | D018316 | 3 | 3 | — | — | — | 5 | ||
| Prostatic neoplasms | D011471 | C61 | — | 4 | — | — | — | 4 | |
| Melanoma | D008545 | 3 | 1 | — | — | — | 4 | ||
| Alveolar soft part sarcoma | D018234 | — | 3 | — | — | — | 3 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Uterine cervical neoplasms | D002583 | 1 | 2 | — | — | — | 3 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | 3 | — | — | — | — | 3 | ||
| Colonic neoplasms | D003110 | C18 | 2 | — | — | — | — | 2 | |
| Ependymoma | D004806 | 2 | — | — | — | — | 2 | ||
| Astrocytoma | D001254 | EFO_0000271 | 2 | — | — | — | — | 2 | |
| Oligodendroglioma | D009837 | EFO_0000631 | 2 | — | — | — | — | 2 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 1 | — | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 1 | — | — | — | — | 1 |
Show 25 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEDIRANIB |
| INN | cediranib |
| Description | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline is an aromatic ether. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 288383-20-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL491473 |
| ChEBI ID | — |
| PubChem CID | 9933475 |
| DrugBank | DB04849 |
| UNII ID | NQU9IPY4K9 (ChemIDplus, GSRS) |
Target
Agency Approved
FLT4
FLT4
KDR
KDR
FLT1
FLT1
KIT
KIT
PDGFRA
PDGFRA
PDGFRB
PDGFRB
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Alternate
CSF1R
CSF1R
FLT3
FLT3
Organism
Homo sapiens
Gene name
CSF1R
Gene synonyms
FMS
NCBI Gene ID
Protein name
macrophage colony-stimulating factor 1 receptor
Protein synonyms
CD115, CD115 antigen, CSF-1 receptor, CSF-1-R, CSF-1R, FMS proto-oncogene, M-CSF-R, macrophage colony stimulating factor I receptor, McDonough feline sarcoma viral (v-fms) oncogene homolog, Proto-oncogene c-Fms
Uniprot ID
Mouse ortholog
Csf1r (12978)
macrophage colony-stimulating factor 1 receptor (Q9DBH9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,728 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
126 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more